Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide in compensated MASH/NASH cirrhosis
2024-513741-36-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2025
- Modality
- Peptides
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Survodutide with Placebo (2 arms). Primary endpoint: Time to first occurrence of composite liver-related clinical endpoint. Planned start Feb 2025; status: authorised.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on 2024-513741-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513741-36-00.